Health
CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…
-
General19 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Noosa News23 hours agoThree steps Queensland SES want you to know to Get Ready for severe weather
-
General24 hours agoRescuers pull children from the rubble of Indonesian boarding school collapse
-
Business22 hours agoDoes Macquarie rate Karoon Energy shares a buy, hold or sell?